Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Company of Biologists
2025-02-01
|
| Series: | Disease Models & Mechanisms |
| Subjects: | |
| Online Access: | http://dmm.biologists.org/content/18/2/DMM050804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202217677586432 |
|---|---|
| author | Stephanie Ling Alex Dexter Alan M. Race Shreya Sharma Gregory Hamm Urszula M. Polanska Rosetta Consortium Cancer Research UK John F. Marshall Zoltan Takats Kevin Brindle Mariia O. Yuneva George Poulogiannis Andrew D. Campbell Owen J. Sansom Richard J. A. Goodwin Josephine Bunch Simon T. Barry |
| author_facet | Stephanie Ling Alex Dexter Alan M. Race Shreya Sharma Gregory Hamm Urszula M. Polanska Rosetta Consortium Cancer Research UK John F. Marshall Zoltan Takats Kevin Brindle Mariia O. Yuneva George Poulogiannis Andrew D. Campbell Owen J. Sansom Richard J. A. Goodwin Josephine Bunch Simon T. Barry |
| author_sort | Stephanie Ling |
| collection | DOAJ |
| format | Article |
| id | doaj-art-611528848c9d4e3dae8cdccf7fff9dbf |
| institution | OA Journals |
| issn | 1754-8403 1754-8411 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | The Company of Biologists |
| record_format | Article |
| series | Disease Models & Mechanisms |
| spelling | doaj-art-611528848c9d4e3dae8cdccf7fff9dbf2025-08-20T02:11:49ZengThe Company of BiologistsDisease Models & Mechanisms1754-84031754-84112025-02-0118210.1242/dmm.050804050804Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibitionStephanie Ling0Alex Dexter1Alan M. Race2Shreya Sharma3Gregory Hamm4Urszula M. Polanska5Rosetta Consortium Cancer Research UK6John F. Marshall7Zoltan Takats8Kevin Brindle9Mariia O. Yuneva10George Poulogiannis11Andrew D. Campbell12Owen J. Sansom13Richard J. A. Goodwin14Josephine Bunch15Simon T. Barry16 Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK National Physical Laboratory, Teddington TW11 0LA, UK National Physical Laboratory, Teddington TW11 0LA, UK National Physical Laboratory, Teddington TW11 0LA, UK Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK https://www.cancergrandchallenges.org/rosetta Barts Cancer Institute, London EC1M 6AU, UK Imperial College London, London SW7 2AZ, UK The Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0QS, UK Francis Crick Institute, London NW1 1AT, UK Institute of Cancer Research, London SW3 6JB, UK CRUK Scotland Institute, Glasgow G61 1BD, UK CRUK Scotland Institute, Glasgow G61 1BD, UK Imaging and Data Analytics, AstraZeneca, Cambridge CB2 0AA, UK National Physical Laboratory, Teddington TW11 0LA, UK Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK http://dmm.biologists.org/content/18/2/DMM050804mass spectrometry imagingimaging mass cytometryspatial multi-omicspi3kaktmtorpharmacodynamic |
| spellingShingle | Stephanie Ling Alex Dexter Alan M. Race Shreya Sharma Gregory Hamm Urszula M. Polanska Rosetta Consortium Cancer Research UK John F. Marshall Zoltan Takats Kevin Brindle Mariia O. Yuneva George Poulogiannis Andrew D. Campbell Owen J. Sansom Richard J. A. Goodwin Josephine Bunch Simon T. Barry Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition Disease Models & Mechanisms mass spectrometry imaging imaging mass cytometry spatial multi-omics pi3k akt mtor pharmacodynamic |
| title | Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition |
| title_full | Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition |
| title_fullStr | Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition |
| title_full_unstemmed | Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition |
| title_short | Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition |
| title_sort | use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mtorc1 2 pathway inhibition |
| topic | mass spectrometry imaging imaging mass cytometry spatial multi-omics pi3k akt mtor pharmacodynamic |
| url | http://dmm.biologists.org/content/18/2/DMM050804 |
| work_keys_str_mv | AT stephanieling useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT alexdexter useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT alanmrace useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT shreyasharma useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT gregoryhamm useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT urszulampolanska useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT rosettaconsortiumcancerresearchuk useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT johnfmarshall useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT zoltantakats useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT kevinbrindle useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT mariiaoyuneva useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT georgepoulogiannis useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT andrewdcampbell useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT owenjsansom useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT richardjagoodwin useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT josephinebunch useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition AT simontbarry useofmetabolicimagingtomonitorheterogeneityoftumourresponsefollowingtherapeuticmtorc12pathwayinhibition |